Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Video: Immunotherapy Tie-Ups Key For Future Of ADC Space

This article was originally published in Scrip

Executive Summary

Richard Onyett, business development director of ADC Therapeutics, chats to Mike Ward, global director of content for Informa Pharma Insights, about developments in the area of antibody drug conjugates (ADCs), a field that seems to have been overshadowed by the recent immunotherapy boom. They discuss how the two fields will combine in the future in oncology and where derailed ADC companies went wrong.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts